TIDMHIK

RNS Number : 8772Z

Hikma Pharmaceuticals Plc

15 January 2020

Annex DTR3

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

All relevant boxes should be completed in block capital letters

 
                                                      State whether the notification 
                                                       relates to (i) a transaction 
                                                       notified in accordance with 
                                                       DTR 3.1.2 R, (ii) a disclosure 
                                                       made in accordance with 
                                                       LR 9.8.6R(1) or (iii) a 
                                                       disclosure made in accordance 
                                                       with section 793 of the 
       Name of the Issuer:                             Companies Act (2006): 
 1.     Hikma Pharmaceuticals PLC               2.     DTR 3.1.2 R 
                                                      State whether notification 
                                                       relates to a person connected 
                                                       with a person discharging 
       Name of person discharging                      managerial responsibilities/ 
        managerial responsibilities/director:          director named in 3 and 
        Said Darwazah, Mazen Darwazah                  identify the connected person: 
 3.     and Ali Al-Husry                        4.     Yes: Darhold Limited 
      ---------------------------------------  ----  ----------------------------------- 
       Indicate whether the notification 
        is in respect of a holding 
        of the person referred to                     Description of shares (including 
        in 3 or 4 above or in respect                  class), debentures or derivatives 
        of a non-beneficial interest:                  or financial instruments 
        Beneficial interest in Darhold                 relating to shares: 
 5.     Limited                                 6.     Ordinary Shares 
      ---------------------------------------  ----  ----------------------------------- 
       Name of registered shareholders(s) 
        and, if more than one, the                    State the nature of the 
        number of shares held by                       transaction: 
        each of them:                                  Release of a pledge over 
 7.     Jordan Kuwait Bank PLC                  8.     2,345,000 Ordinary Shares 
      ---------------------------------------  ----  ----------------------------------- 
                                                      Percentage of issued class 
                                                       acquired (treasury shares 
       Number of shares, debentures                    of that class should not 
        or financial instruments                       be taken into account when 
        relating to shares acquired:                   calculating percentage): 
 9.     None                                    10.    N/A 
      ---------------------------------------  ----  ----------------------------------- 
                                                      Percentage of issued class 
                                                       disposed (treasury shares 
       Number of shares, debentures                    of that class should not 
        or financial instruments                       be taken into account when 
        relating to shares disposed:                   calculating percentage): 
 11.    None                                    12.    N/A 
      ---------------------------------------  ----  ----------------------------------- 
       Price per share or value 
        of transaction:                               Date and place of transaction: 
 13.    N/A                                     14.    Amman, 15 January 2020 
      ---------------------------------------  ----  ----------------------------------- 
       Total holding following 
        notification and total percentage 
        holding following notification 
        (any treasury shares should 
        not be taken into account                     Date issuer informed of 
        when calculating percentage):                  transaction: 
 15.    60,000,000 - 24.76 per cent.            16.    15 January 2020 
      ---------------------------------------  ----  ----------------------------------- 
 
 
 If a person discharging managerial responsibilities has been 
  granted options by the issuer complete the following boxes 
------------------------------------------------------------------------------ 
                                                Period during which or date 
 17.   Date of grant                      18.    on which exercisable 
      ---------------------------------  ----  ------------------------------- 
       Total amount paid (if                    Description of shares or 
        any) for grant of the                    debentures involved (class 
 19.    option                            20.    and number) 
      ---------------------------------  ----  ------------------------------- 
       Exercise price (if fixed 
        at time of grant) or indication         Total number of shares or 
        that price is to be fixed                debentures over which options 
 21.    at the time of exercise           22.    held following notification 
      ---------------------------------  ----  ------------------------------- 
                                                Name of contact and telephone 
 23.   Any additional information         24.    number for queries 
      ---------------------------------  ----  ------------------------------- 
 
 
 Name of authorised official or issuer responsible for making 
  notification 
 Peter Speirs, Company Secretary, Hikma Pharmaceuticals PLC 
 Date of notification: 15 January 2020 
 

Notes:

This form is intended for use by an issuer to make a RIS notification required by DTR 3.1.4

(1) An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2) An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3) An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4) An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHGCGDBBSBDGGU

(END) Dow Jones Newswires

January 15, 2020 04:46 ET (09:46 GMT)

Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Hikma Pharmaceuticals